Oncology patient preferences in reporting on symptoms

Alyssa L. Peechatka, Millie Gerzon, Jenny J. Ly, Susan M. Dallabrida

Abstract

Background: Collecting patient reported outcomes (PROs) in oncology clinical trials is becoming increasingly important. However, there is limited consensus on the most appropriate frequency of PRO administration in oncology trials.  The aim of this preliminary study is to examine the perspective of participants with a cancer diagnosis on the importance of completing PROs and to identify at what frequency participants prefer to report on their cancer-related symptoms.

Methods: 166 participants with a self-reported cancer diagnosis completed a multiple-choice online survey regarding perceptions of symptom importance and reporting preferences.

Results: When asked about the benefit of reporting oncology-related symptoms daily, 44% of participants indicated there would be “very much” a benefit, 29% indicated there would be “quite a bit” of benefit, and 17% indicated there would be “somewhat” of a benefit. When asked about how frequently they would prefer to report symptoms, 41% of participants preferred “as they occur,” 36% preferred “once a day,” 18% preferred “once a week,” 4% preferred “twice a day,” and 1% preferred “every 4 hours”.

Conclusions: PROs in oncology clinical research are most often collected at weekly, monthly, or longer intervals; however, meaningful fluctuations in cancer-related symptoms can occur more frequently. While concerns regarding patient burden are often raised to support infrequent reporting, these data suggest that participants would like to report symptoms with greater frequency, as episodic and daily reporting options were most popular. Based on these data, more frequent PRO data capture is not only feasible but perceived as important by individuals with cancer.

Keywords

Patient reported outcomes, Oncology, Frequency, Symptoms

Full Text:

PDF

References

U.S. Food and Drug Administration. Hematology/oncology (cancer) approvals & safety notifications. Available at: https://www.fda.gov/ drugs/resources-information-approved-drugs/ hematologyoncology-cancer-approvals-safety-notifications. Accessed 15 May 2019.

Kleutz PG, O’Connor DJ, Soltys K. Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol. 2018;19(5):e267-e274.

U.S. Department of Health and Human Services, Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry 2018. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics. Accessed on 15 May 2019.

European Medicine’s Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: The use of patient-reported outcome (PRO) measures in oncology studies 2016. Available at: https://www.ema.europa.eu/en /documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. Accessed 15 May, 2019.

Berry DL, Blumenstein BA, Halpenny B, Wolpin S, Fann JR, Austin-Seymour M, et al. Enhancing patient-provider communication with the electronic self-report assessment for cancer: A randomized trial. J Clin Oncol. 2011;29(8):1029-35.

Hilarius DL, Kloeg PH, Gundy CM, Aaronson NK. Use of health-related quality-of-life assessments in daily clinical oncology nursing practice. Cancer. 2008;113(3):628-37.

Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication. JAMA. 2002;228(23):3027-4.

McLachlan S, Allenby A, Matthews J, Wirth A, Kissane D, Bishop M, et al. Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer. J Clin Oncol. 2001;19(21):4117-25.

Cleeland CS, Wang XS, Shi Q, Mendoza TR, Wright SL, Berry MD, et al. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: A randomized controlled clinical trial. J Clin Oncol. 2011;29(8):994-1000.

Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized control trial. J Clin Oncol. 2016;34(6):557-65.

Seow H, King S, Green E, Pereira J, Sawka C. Perspectives of patients on the utility of electronic patient-reported outcomes on cancer care. J Clin Oncol. 2011;29(31):4213-4.

Jim HSL, Small B, Faul LA, Franzen J, Apte S, Jacobsen PB. Fatigue, Depression, Sleep, and Activity During Chemotherapy: Daily and Intraday Variation and Relationships Among Symptom Changes. Ann Behav Med. 2011;42(3):321-33.

de Jong N, Kester ADM, Schouten HC, Abu-Saad HH, Courtens AM. Course of fatigue between two cycles of adjuvant chemotherapy in breast cancer patients. Cancer Nurs. 2006;29(6):467-47.

Badr H, Basen-Engquist K, Taylor CLC, de Moor C. Mood states associated with transitory physical symptoms among breast and ovarian cancer survivors. J Behav Med. 2006;29(5):461-75.

Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25(32):1521-7.

Atkinson TM, Schwartz CE, Goldstein L, Garcia I, Storder DF, Li Y, et al. Perceptions of response burden associated with completion of patient-reported outcome assessments in oncology. Value Health. 2019;22(2):115-230.

Ring AE, Cheong KA, Watkins CL, Meddis D, Cella D, Harper PG. A randomized study of electronic diary versus paper and pencil collection of patient-reported outcomes in patients with non-small cell lung cancer. Patient. 2008;1(2):105-13.

Abernathy AP, Herndon JE, Wheeler JL. Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: Pilot study of an e/tablet data collection system in academic oncology. J Pain Symptom Manage. 2009:37(6):1027-38.

Roydhouse JK, King-Kallimanis BL, Howie LJ, Singh H, Kluetz PG. Blinding and patient-reported outcome completion rates in US food and drug administration cancer trial submissions. JNCI. 2019;111(5):459-64.